Verve
PrivateLast Round
M&A
Jun 17, 2025
Est. Valuation
$1.3B
Total Funding Raised
$359.3M
Company Overview
Verve operates in Healthcare & Life Sciences and is based in Cambridge, Massachusetts. Its latest recorded funding round was a Follow-on Offering round in December 2023.
Verve Therapeutics (NAS: VERV) is a biotechnology company focused on developing innovative gene editing therapies to address cardiovascular disease through single-course treatments targeting key genetic factors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Verve Comparables
Compare Verve with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Beijing Innova Medicine Technology Co., Ltd. | 62% | |
| Mammoth Biosciences | 60% | |
| Aqur Biosciences, Inc. | 54% |
For institutional investors. Book with your work email.
Verve Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| M&A | Jun 17, 2025 | ||||
| Follow-on Offering | Dec 1, 2023 | ||||
| Private Placement | Dec 1, 2023 | ||||
| IPO | Jun 17, 2021 | ||||
| Series B | Jan 19, 2021 | ||||
Series A Extension | Jun 11, 2020 |
For institutional investors. Book with your work email.
Verve Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Redmile Group | Series B |
| Jefferies | IPO |
| Janus Henderson Group | Series B |
| RA Capital Management | Series B |
| GV | Series B, Series A Extension, Series A |
| Guggenheim Securities | IPO |
| F-Prime Capital | Series A Extension, Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 19, 2021
$94M round led by Wellington Management and Casdin Capital.
For institutional investors. Book with your work email.
Verve Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Verve's valuation, stock price, and market status.
Is Verve a public or private company?
Verve is a private company.
What is the current stock price of Verve?
Verve is a private company, so its shares have no public market price. Caplight tracks Verve's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Verve worth (valuation)?
Verve's valuation is estimated at $1.3B based on funding round data.
Can I buy Verve stock?
Verve shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Verve's last funding round?
Verve's most recent funding round was M&A on June 17, 2025.
Who are the main investors in Verve?
Key investors in Verve include Jefferies, GV, Guggenheim Securities, Wellington Management, Casdin Capital.
Will Verve IPO soon?
No public IPO plans have been announced for Verve.
How can I track Verve secondary market activity?
Caplight tracks bids, offers, and trades in Verve's shares on secondary markets.